Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Sell
32
MED Quote, Financials, Valuation and Earnings
Last price:
$12.50
Seasonality move
:
20.82%
Day range:
$11.72 - $12.53
52-week range:
$11.57 - $29.63
Dividend yield:
0%
P/E ratio:
69.44x
P/S ratio:
0.23x
P/B ratio:
0.65x
Volume:
303.4K
Avg. volume:
230.1K
1-year change:
-64.8%
Market cap:
$136.7M
Revenue:
$602.5M
EPS (TTM):
$0.18
Analysts' Opinion
-
Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.00, Medifast has an estimated upside of 20% from its current price of $12.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing -20% downside risk from its current price of $12.50.
Fair Value
-
According to the consensus of 1 analyst, Medifast has 20% upside to fair value with a price target of $15.00 per share.
MED vs. S&P 500
-
Over the past 5 trading days, Medifast has overperformed the S&P 500 by 0.56% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Medifast does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Medifast revenues have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Medifast reported revenues of $119M.
Earnings Growth
-
Medifast earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Medifast reported earnings per share of $0.07.
Enterprise value:
-25.6M
EV / Invested capital:
--
Price / LTM sales:
0.23x
EV / EBIT:
-8.90x
EV / Revenue:
-0.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.51x
Price / Operating cash flow:
8.05x
Enterprise value / EBITDA:
-1.64x
Gross Profit (TTM):
$444.6M
Return On Assets:
0.71%
Net Income Margin (TTM):
0.35%
Return On Equity:
1.01%
Return On Invested Capital:
1.01%
Operating Margin:
0.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.6B | $1.1B | $602.5M | $191M | $119M | |
| Gross Profit | $1.1B | $775.9M | $444.6M | $141.4M | $88.2M | |
| Operating Income | $184.8M | $126.4M | $2.9M | $8.7M | $709K | |
| EBITDA | $195.7M | $139.5M | $15.6M | $12M | $3.9M | |
| Diluted EPS | $12.71 | $9.06 | $0.18 | $0.50 | $0.07 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $234.3M | $306.9M | $222.8M | $224M | $214.4M | |
| Total Assets | $276.1M | $398.3M | $316.2M | $309.9M | $284.2M | |
| Current Liabilities | $111.4M | $169.8M | $140.9M | $92.3M | $64.2M | |
| Total Liabilities | $118.8M | $195.9M | $161.2M | $108.4M | $74.1M | |
| Total Equity | $157.2M | $202.5M | $155M | $201.5M | $210.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $194.6M | $147.7M | $24.5M | $10.5M | -$4.9M | |
| Cash From Investing | -$11.4M | -$61M | -$26.5M | -$10.7M | -$19.4M | |
| Cash From Financing | -$199.6M | -$79.8M | -$1.5M | -$17.9M | -$1K | |
| Free Cash Flow | $177.9M | $141.2M | $17M | $9.6M | -$7.2M | |
MED
Sector
Market Cap
$136.7M
$260.2M
Price % of 52-Week High
42.19%
73.59%
Dividend Yield
0%
0%
Shareholder Yield
0.43%
3.16%
1-Year Price Total Return
-64.8%
-9.69%
Beta (5-Year)
1.056
0.419
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
34.18%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$12.24
200-day SMA
Sell
Level
$17.14
Bollinger Bands (100)
Sell
Level
13.1 - 17.68
Chaikin Money Flow
Buy
Level
41.3M
20-day SMA
Sell
Level
$12.65
Relative Strength Index (RSI14)
Sell
Level
43.45
ADX Line
Sell
Level
24.66
Williams %R
Neutral
Level
-52.7704
50-day SMA
Sell
Level
$13.66
MACD (12, 26)
Sell
Level
-0.42
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Sell
Level
-15M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2188)
Buy
CA Score
(Annual)
Level (1.261)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (22.8248)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Stock Forecast FAQ
In the current month, MED has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MED average analyst price target in the past 3 months is $15.00.
-
Where Will Medifast Stock Be In 1 Year?
According to analysts, the consensus estimate is that Medifast share price will rise to $15.00 per share over the next 12 months.
-
What Do Analysts Say About Medifast?
Analysts are divided on their view about Medifast share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Medifast is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Medifast's Price Target?
The price target for Medifast over the next 1-year time period is forecast to be $15.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Medifast is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of MED?
You can purchase shares of Medifast via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Medifast shares.
-
What Is The Medifast Share Price Today?
Medifast was last trading at $12.50 per share. This represents the most recent stock quote for Medifast. Yesterday, Medifast closed at $12.50 per share.
-
How To Buy Medifast Stock Online?
In order to purchase Medifast stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is up 23.1% over the past day.
Sell
35
RGC alert for Apr 30
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 14.88% over the past day.
